OnDemand WTP Pricing Research

Sanofi to Start Offering Discounts on Two Insulin Products | AJMC.com

The discount to patients comes as Sanofi, Eli Lilly, and Novo Nordisk are parties in a racketeering lawsuit where they recently acknowledged that consumers’ sticker shock over insulin prices are real. It’s just not the manufacturers’ fault, they argue, and it’s definitely not a crime. “Defendants acknowledge that pharmaceutical pricing is an important issue, especially given how recent trends in the design of insurance benefits have affected certain patients’ out of pocket costs,” stated the joint motion filed on March 9, 2018, by attorneys for the 3 companies.

The cost of insulin has drawn attention from the World Health Organization, which made the plight of patients the focus of World Health Day in 2 years ago. Robert A. Gabbay, MD, PhD, FACP, chief medical officer for Joslin Diabetes Center, wrote about the difficult dynamics of insulin pricing in an issue of Evidence-Based Diabetes Management™, for which he is the editor-in-chief.

Last month, FDA Commissioner Scott Gottlieb, MD, criticized a reimbursement system that relies on rebates passed between pharmaceutical companies and pharmacy benefit managers (PBMs), and said prices are not transparent. Speaking at a meeting of America’s Health Insurance Plans, Gottlieb said, “we continue to see a backlash against these Kabuki drug-pricing constructs—constructs that obscure profit taking across the supply chain that drives up costs; that expose consumers to high out-of-pocket spending; and that actively discourage competition.”

Amid the uproar over rising drug prices, some insurers, such as UnitedHealthcare and Aetna, are passing drug rebates back to consumers.

Read complete article here:

Sanofi to Start Offering Discounts on Two Insulin Products.